Unknown

Dataset Information

0

Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.


ABSTRACT:

Background

The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC) versus ASC alone in aESCC.

Methods

We conducted a tri-center retrospective cohort study (n = 166) including patients with aESCC who had experienced disease progression on palliative first-line therapy. A propensity score model using inverse probability of treatment weighting (IPTW) was implemented for comparative efficacy analysis of overall survival (OS) in patients with second-line + ASC (n = 92, 55%) versus ASC alone (n = 74, 45%).

Results

The most frequent second-line regimens used were docetaxel (36%) and paclitaxel (18%). In unadjusted primary endpoint analysis, second-line + ASC was associated with significantly longer OS compared with ASC alone [hazard ratio (HR) = 0.49, 95% confidence interval (CI): 0.35-0.69, p < 0.0001]. However, patients in the second-line + ASC group were characterized by more favorable baseline features including a better Eastern Cooperative Oncology Group (ECOG) performance status, a longer first-line treatment duration and lower C-reactive protein levels. After rigorous adjusting for baseline confounders by re-weighting the data with the IPTW the favorable association between second-line and longer OS weakened but prevailed. The median OS was 6.1 months in the second-line + ASC group and 3.2 months in the ASC group, respectively (IPTW-adjusted HR = 0.40, 95% CI: 0.24-0.69, p = 0.001). Importantly, the benefit of second-line was consistent across several clinical subgroups, including patients with ECOG performance status ⩾1 and age ⩾65 years. The most common grade 3 or 4 adverse events associated with palliative second-line therapy were hematological toxicities.

Conclusion

This real-world study supports the concept that systemic second-line therapy prolongs survival in patients with aESCC.

SUBMITTER: Muller M 

PROVIDER: S-EPMC8488508 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6447553 | biostudies-literature
| S-EPMC9058306 | biostudies-literature
| S-EPMC5391716 | biostudies-literature
| S-EPMC6964023 | biostudies-literature
| S-EPMC8634950 | biostudies-literature
| S-EPMC7467430 | biostudies-literature
| S-EPMC10362607 | biostudies-literature
| S-EPMC8421963 | biostudies-literature
| S-EPMC9708733 | biostudies-literature
| S-EPMC10227428 | biostudies-literature